• Vidac Pharma plans to establish French unit Eutopos Pharma in Strasbourg to expand its operating footprint in continental Europe.
• Eutopos was selected for Quest for Health, a Strasbourg-based health and life-sciences accelerator tied to the cross-border BioValley cluster.
• The unit is positioned as a European platform for R&D, clinical trials, business development, partnerships, licensing.
• Séverine Sigrist was named designated CEO; Max Herzberg will chair the board and strategic committee once the company is formed.
• Expansion is intended to deepen links with pharma groups, academia, investors across Europe while advancing oncology and onco-dermatology programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vidac Pharma Holding plc published the original content used to generate this news brief via pressetext (Ref. ID: 202607150100PRESSTXTEUPR__DE95231798A9674CE67C1603CA6949AD8) on July 15, 2026, and is solely responsible for the information contained therein.